|
US20110196039A9
(en)
*
|
1994-10-05 |
2011-08-11 |
Kaesemeyer Wayne H |
Controlled release arginine formulations
|
|
DE19545257A1
(de)
|
1995-11-24 |
1997-06-19 |
Schering Ag |
Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
|
|
EP0998940A1
(en)
*
|
1998-09-30 |
2000-05-10 |
Laboratoire Theramex |
Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of LH-RH analogues
|
|
PT1158014E
(pt)
|
1998-12-15 |
2005-04-29 |
Takeda Pharmaceutical |
Processo para a producao de poliesteres biodegradaveis
|
|
JP2002539172A
(ja)
|
1999-03-17 |
2002-11-19 |
ノバルティス アクチエンゲゼルシャフト |
Ｔｇｆ−ベータを含む医薬組成物
|
|
MXPA02000461A
(es)
|
1999-07-15 |
2002-07-30 |
Takeda Chemical Industries Ltd |
Composiciones de liberacion prolongada, metodos para producir las mismas y uso de estas.
|
|
US6303138B1
(en)
|
1999-09-17 |
2001-10-16 |
Depuy Orthopaedics |
Endothelin-based compositions for enhancing connective tissue repair
|
|
ATE309822T1
(de)
|
2000-04-19 |
2005-12-15 |
Genentech Inc |
Formulierungen mit verzögerter freisetzung enthaltend wachstumshormon
|
|
KR20030031480A
(ko)
*
|
2000-04-28 |
2003-04-21 |
프지오메드, 인코포레이티드 |
폴리산 및 폴리알킬렌 옥사이드의 지혈 조성물 및 이들의이용 방법
|
|
US20050042194A1
(en)
|
2000-05-11 |
2005-02-24 |
A.P. Pharma, Inc. |
Semi-solid delivery vehicle and pharmaceutical compositions
|
|
JP2002003406A
(ja)
*
|
2000-06-21 |
2002-01-09 |
Sankyo Co Ltd |
脳血管攣縮予防製剤
|
|
US7019106B2
(en)
*
|
2000-08-07 |
2006-03-28 |
Wako Pure Chemical Industries, Ltd. |
Lactic acid polymer and process for producing the same
|
|
US7252842B2
(en)
|
2000-12-21 |
2007-08-07 |
Alrise Biosystems Gmbh |
Induced phase transition method for the production of microparticles containing hydrophilic active agents
|
|
GB0100761D0
(en)
|
2001-01-11 |
2001-02-21 |
Biocompatibles Ltd |
Drug delivery from stents
|
|
DE60231862D1
(de)
*
|
2001-02-23 |
2009-05-20 |
Genentech Inc |
Erodierbare polymere zur injektion
|
|
US6558702B2
(en)
*
|
2001-04-13 |
2003-05-06 |
Alkermes Controlled Therapeutics, Inc. |
Method of modifying the release profile of sustained release compositions
|
|
EP1382350A4
(en)
*
|
2001-04-25 |
2006-01-04 |
Takeda Pharmaceutical |
MEANS AGAINST THE PROPHYLAXIS BEFORE POSTOPERATIVE REPEAT OF PREMOPEOPAUSAL BREAST CANCER
|
|
AU2002320122B2
(en)
*
|
2001-06-21 |
2007-07-26 |
Genentech, Inc. |
Sustained release formulation
|
|
TWI332407B
(en)
|
2001-06-29 |
2010-11-01 |
Takeda Chemical Industries Ltd |
Controlled release composition and method of producting the same
|
|
GB0122113D0
(en)
*
|
2001-09-11 |
2001-10-31 |
Astrazeneca Ab |
Composition
|
|
DE60231549D1
(de)
*
|
2001-12-03 |
2009-04-23 |
Dor Biopharma Inc |
Stabilisierte umkehr-mizellen-zusammensetzungen und ihre verwendung
|
|
JP2003192773A
(ja)
*
|
2001-12-26 |
2003-07-09 |
Mitsui Chemicals Inc |
生体吸収性ポリヒドロキシカルボン酸及びその製造法
|
|
EP1488807A4
(en)
*
|
2002-03-11 |
2009-07-08 |
Takeda Pharmaceutical |
MEANS FOR THE TREATMENT OF SEXUAL-HORMONE-RELATED DISEASES
|
|
PT1532985T
(pt)
*
|
2002-06-25 |
2017-01-20 |
Takeda Pharmaceuticals Co |
Processo de produção de uma composição de libertação sustentada
|
|
WO2004081196A2
(en)
*
|
2003-03-11 |
2004-09-23 |
Qlt Usa Inc. |
Formulations for cell- schedule dependent anticancer agents
|
|
US7833545B2
(en)
*
|
2003-04-29 |
2010-11-16 |
The General Hospital Corporation |
Methods and devices for the sustained release of multiple drugs
|
|
US20040244806A1
(en)
*
|
2003-06-09 |
2004-12-09 |
Ferree Bret A. |
Treating disc herniation and other conditions with leukocytes
|
|
US20050025825A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Xanodyne Pharmacal, Inc. |
Tranexamic acid formulations with reduced adverse effects
|
|
US20090214644A1
(en)
*
|
2003-07-31 |
2009-08-27 |
Xanodyne Pharmaceuticals, Inc. |
Tranexamic acid formulations with reduced adverse effects
|
|
KR101087464B1
(ko)
|
2003-08-08 |
2011-11-25 |
밸리언트 인터내셔널(바베이도스) 에스알엘 |
부프로피온 히드로클로라이드의 개질 방출형 정제
|
|
GB0320806D0
(en)
|
2003-09-05 |
2003-10-08 |
Astrazeneca Ab |
Therapeutic treatment
|
|
US20050112170A1
(en)
*
|
2003-11-20 |
2005-05-26 |
Hossainy Syed F. |
Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same
|
|
US8846069B2
(en)
|
2003-11-20 |
2014-09-30 |
Abbott Cardiovascular Systems Inc. |
Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same
|
|
TW200529890A
(en)
*
|
2004-02-10 |
2005-09-16 |
Takeda Pharmaceutical |
Sustained-release preparations
|
|
US20050245614A1
(en)
*
|
2004-03-04 |
2005-11-03 |
Xanodyne Pharmaceuticals, Inc. |
Tranexamic acid formulations
|
|
US8022106B2
(en)
*
|
2004-03-04 |
2011-09-20 |
Ferring B.V. |
Tranexamic acid formulations
|
|
US20050244495A1
(en)
|
2004-03-04 |
2005-11-03 |
Xanodyne Pharmaceuticals, Inc. |
Tranexamic acid formulations
|
|
US7947739B2
(en)
|
2004-03-04 |
2011-05-24 |
Ferring B.V. |
Tranexamic acid formulations
|
|
US20090215898A1
(en)
*
|
2004-03-04 |
2009-08-27 |
Xanodyne Pharmaceuticals, Inc. |
Tranexamic acid formulations
|
|
US20060094651A1
(en)
*
|
2004-11-03 |
2006-05-04 |
Cyrus Karkaria |
Formulations and methods of production of FGF-20
|
|
EP1768650B1
(en)
*
|
2004-06-04 |
2008-07-16 |
Camurus Ab |
Liquid depot formulations
|
|
WO2005122734A2
(en)
*
|
2004-06-14 |
2005-12-29 |
The Research Foundation Of State University Of New York |
Nanosphere/microsphere delivery system for the treatment of spinal cord injury
|
|
TW200613012A
(en)
*
|
2004-07-02 |
2006-05-01 |
Takeda Pharmaceuticals Co |
Sustained-release composition, process for producing the same and use of the same
|
|
US20060039890A1
(en)
*
|
2004-08-20 |
2006-02-23 |
Renshaw Perry F |
Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
|
|
US20060068010A1
(en)
*
|
2004-09-30 |
2006-03-30 |
Stephen Turner |
Method for improving the bioavailability of orally delivered therapeutics
|
|
US8313763B2
(en)
*
|
2004-10-04 |
2012-11-20 |
Tolmar Therapeutics, Inc. |
Sustained delivery formulations of rapamycin compounds
|
|
WO2006041942A2
(en)
*
|
2004-10-04 |
2006-04-20 |
Qlt Usa, Inc. |
Ocular delivery of polymeric delivery formulations
|
|
US9649382B2
(en)
|
2005-01-14 |
2017-05-16 |
Camurus Ab |
Topical bioadhesive formulations
|
|
PL1843746T3
(pl)
*
|
2005-01-14 |
2011-09-30 |
Camurus Ab |
Formulacje analogów somatostatyny
|
|
ES2343641T3
(es)
|
2005-01-14 |
2010-08-05 |
Camurus Ab |
Formulaciones bioadhesivas topicas.
|
|
WO2006077362A1
(en)
|
2005-01-21 |
2006-07-27 |
Camurus Ab |
Pharmaceutical lipid compositions
|
|
EP1866319B1
(en)
|
2005-04-01 |
2011-11-23 |
The Regents of The University of California |
Phosphono-pent-2-en-1-yl nucleosides and analogs
|
|
US20090156545A1
(en)
*
|
2005-04-01 |
2009-06-18 |
Hostetler Karl Y |
Substituted Phosphate Esters of Nucleoside Phosphonates
|
|
ATE382337T1
(de)
*
|
2005-04-28 |
2008-01-15 |
Nipro Corp |
Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer
|
|
CN101217940B
(zh)
*
|
2005-06-06 |
2013-03-27 |
卡穆鲁斯公司 |
Glp-1类似物制剂
|
|
US8097239B2
(en)
*
|
2005-06-06 |
2012-01-17 |
Camurus Ab |
Controlled-release formulations
|
|
WO2007029361A1
(ja)
*
|
2005-09-02 |
2007-03-15 |
Takeda Pharmaceutical Company Limited |
短鎖デオキシリボ核酸又は短鎖リボ核酸含有徐放性マイクロスフェア及びその製造法
|
|
ES2383303T3
(es)
|
2005-11-10 |
2012-06-20 |
Chemi S.P.A. |
Formulaciones de inhibidores de la liberación prolongada de la hormona del crecimiento análogos de la somatostatina
|
|
JP5738516B2
(ja)
|
2005-12-30 |
2015-06-24 |
ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド |
心機能改善のためのニューレグリンの徐放
|
|
WO2007106537A2
(en)
*
|
2006-03-13 |
2007-09-20 |
Activx Biosciences, Inc. |
Aminoquinolones as gsk-3 inhibitors
|
|
CA2644784A1
(en)
*
|
2006-03-13 |
2007-09-20 |
Jinling Chen |
Formulations of sitaxsentan sodium
|
|
AU2007225139A1
(en)
*
|
2006-03-13 |
2007-09-20 |
Encysive Pharmaceuticals, Inc. |
Methods and compositions for treatment of diastolic heart failure
|
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
|
CN101535304A
(zh)
|
2006-09-21 |
2009-09-16 |
埃迪威克斯生物科学公司 |
丝氨酸水解酶抑制剂
|
|
BRPI0715579A2
(pt)
|
2006-10-19 |
2015-05-26 |
Auspex Pharmaceuticals Inc |
"composto, composição farmacêutica e uso de um composto"
|
|
WO2008057604A2
(en)
*
|
2006-11-08 |
2008-05-15 |
The Regents Of The University Of California |
Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
|
|
US7713541B1
(en)
|
2006-11-21 |
2010-05-11 |
Abbott Cardiovascular Systems Inc. |
Zwitterionic terpolymers, method of making and use on medical devices
|
|
JP4564098B2
(ja)
|
2006-12-18 |
2010-10-20 |
武田薬品工業株式会社 |
徐放性組成物およびその製造法
|
|
US8974801B2
(en)
*
|
2006-12-21 |
2015-03-10 |
Amphastar Pharmaceuticals Inc. |
Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
|
|
WO2008079371A1
(en)
*
|
2006-12-22 |
2008-07-03 |
Encysive Pharmaceuticals, Inc. |
Modulators of c3a receptor and methods of use thereof
|
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
|
BRPI0808089A2
(pt)
*
|
2007-02-28 |
2014-07-15 |
Conatus Pharmaceuticals Inc |
Método para tratar uma doença do fígado, para diminuir um nível elevado de uma enzima do fígado, para inibir uma cascata de sinalização de tnf-alfa e uma cascata de sinalização de alfa-faz, para reduzir um dano ao fígado, para suprimir a apoptose excessiva em uma célula de fígado, e para inibir a replicação do vírus da hepatite c.
|
|
ES2693948T3
(es)
|
2007-03-15 |
2018-12-14 |
Auspex Pharmaceuticals, Inc. |
Fenetilamina sustituida con actividad serotoninérgica y/o norepinefrinérgica
|
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
|
GB0711656D0
(en)
*
|
2007-06-15 |
2007-07-25 |
Camurus Ab |
Formulations
|
|
MX2010000465A
(es)
*
|
2007-07-12 |
2010-08-30 |
Tragara Pharmaceuticals Inc |
Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
|
|
GB0716385D0
(en)
|
2007-08-22 |
2007-10-03 |
Camurus Ab |
Formulations
|
|
CN101855228B
(zh)
*
|
2007-09-11 |
2012-10-24 |
杏林制药株式会社 |
作为gsk-3抑制剂的氰基氨基喹诺酮和四唑并氨基喹诺酮
|
|
US8476261B2
(en)
|
2007-09-12 |
2013-07-02 |
Kyorin Pharmaceutical Co., Ltd. |
Spirocyclic aminoquinolones as GSK-3 inhibitors
|
|
EP2886105B1
(en)
|
2007-10-24 |
2018-12-05 |
Camurus Ab |
Controlled-release formulations
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
PL2947072T3
(pl)
|
2008-03-17 |
2017-05-31 |
Ambit Biosciences Corporation |
1-(3-(6,7-dimetoksychinazolin-4-yloksy)fenylo)-3-(5-(1,1,1-trifluoro-2-metylopropan-2-ylo)izoksazol-3-ilo)mocznik jako modulator kinazy RAF w leczeniu chorób nowotworowych
|
|
US20090298882A1
(en)
*
|
2008-05-13 |
2009-12-03 |
Muller George W |
Thioxoisoindoline compounds and compositions comprising and methods of using the same
|
|
AU2009249600A1
(en)
*
|
2008-05-20 |
2009-11-26 |
Cerenis Therapeutics Holding S.A. |
Niacin and NSAID for combination therapy
|
|
WO2010014134A1
(en)
|
2008-07-02 |
2010-02-04 |
Idenix Pharamaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
CA2730760A1
(en)
*
|
2008-07-16 |
2010-01-21 |
Surmodics Pharmaceuticals, Inc. |
Process for preparing microparticles containing bioactive peptides
|
|
GB0815435D0
(en)
|
2008-08-22 |
2008-10-01 |
Camurus Ab |
Formulations
|
|
JP2012512163A
(ja)
*
|
2008-12-11 |
2012-05-31 |
エーピー ファーマ， インコーポレイテッド |
ポリオルトエステルおよびそれらの製剤の安定性を高めるための方法
|
|
EP2376524B1
(en)
|
2008-12-31 |
2017-03-15 |
Cypralis Limited |
Derivatives of cyclosporin a
|
|
EP2601934A1
(en)
|
2009-01-22 |
2013-06-12 |
Ludwig-Maximilians-Universität München |
Vesicular phospholipid gels comprising proteinaceous substances
|
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
|
PL2401267T3
(pl)
*
|
2009-02-27 |
2014-06-30 |
Ambit Biosciences Corp |
Pochodne chinazoliny modulujące kinazę JAK i ich zastosowanie w metodach
|
|
JP5690286B2
(ja)
|
2009-03-04 |
2015-03-25 |
イデニク プハルマセウティカルス，インコーポレイテッド |
ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
|
|
JP2012520314A
(ja)
|
2009-03-11 |
2012-09-06 |
アムビト ビオスシエンセス コルポラチオン |
癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
|
|
KR101748891B1
(ko)
*
|
2009-03-11 |
2017-06-19 |
교린 세이야꾸 가부시키 가이샤 |
Ｇｓｋ-3 억제제로서의 7-시클로알킬아미노퀴놀론
|
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
|
AU2010229468A1
(en)
|
2009-03-27 |
2011-10-13 |
Vetdc, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
AR076363A1
(es)
|
2009-04-22 |
2011-06-08 |
Axikin Pharmaceuticals Inc |
Antagonistas de ccr3 de arilsulfonamida
|
|
SG175748A1
(en)
|
2009-04-22 |
2011-12-29 |
Axikin Pharmaceuticals Inc |
2,5-disubstituted arylsulfonamide ccr3 antagonists
|
|
PE20120810A1
(es)
|
2009-04-22 |
2012-07-08 |
Axikin Pharmaceuticals Inc |
Compuestos derivados de 5-ciano-2-(feniltio)bencensulfonamida como antagonistas de ccr3
|
|
US20100280117A1
(en)
*
|
2009-04-30 |
2010-11-04 |
Xanodyne Pharmaceuticals, Inc. |
Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
|
|
WO2011003870A2
(en)
|
2009-07-06 |
2011-01-13 |
Creabilis S.A. |
Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
|
|
US8486939B2
(en)
|
2009-07-07 |
2013-07-16 |
Pathway Therapeutics Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
|
ES2655883T5
(es)
|
2009-07-08 |
2022-04-18 |
Hope Medical Entpr Inc D B A Hope Pharmaceuticals |
Composiciones farmacéuticas que contienen tiosulfato de sodio
|
|
EP2467144A1
(en)
|
2009-07-24 |
2012-06-27 |
ViroLogik GmbH |
Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
|
|
US9284307B2
(en)
|
2009-08-05 |
2016-03-15 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors
|
|
BR112012003661A2
(pt)
|
2009-08-19 |
2017-04-25 |
Ambit Biosciences Corp |
"compostos de biarila e métodos de uso dos mesmos."
|
|
TW201120037A
(en)
|
2009-10-26 |
2011-06-16 |
Sunesis Pharmaceuticals Inc |
Compounds and methods for treatment of cancer
|
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
|
WO2011064769A1
(en)
|
2009-11-24 |
2011-06-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods and pharmaceutical compositions for the treatment of hot flashes
|
|
US20110301235A1
(en)
|
2009-12-02 |
2011-12-08 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
|
SG181797A1
(en)
|
2009-12-18 |
2012-07-30 |
Idenix Pharmaceuticals Inc |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
|
EP2515654A4
(en)
*
|
2009-12-23 |
2013-04-24 |
Map Pharmaceuticals Inc |
NEW ERGOLINANALOGA
|
|
AU2010339460A1
(en)
|
2009-12-30 |
2012-07-19 |
Scynexis Inc. |
Cyclosporine analogues
|
|
WO2011089166A1
(en)
|
2010-01-19 |
2011-07-28 |
Virologik Gmbh |
Semicarbazone proteasome inhibitors for treating hiv and hepatitis infection
|
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
|
US9138309B2
(en)
|
2010-02-05 |
2015-09-22 |
Allergan, Inc. |
Porous materials, methods of making and uses
|
|
US9205577B2
(en)
*
|
2010-02-05 |
2015-12-08 |
Allergan, Inc. |
Porogen compositions, methods of making and uses
|
|
EP2531197B1
(en)
|
2010-02-05 |
2017-05-17 |
Tragara Pharmaceuticals, Inc. |
Solid state forms of macrocyclic kinase inhibitors
|
|
SG10201501062SA
(en)
|
2010-02-11 |
2015-04-29 |
Celgene Corp |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
|
|
EP2542542B1
(en)
|
2010-03-02 |
2015-04-22 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide ccr3 antagonists
|
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
|
WO2011116161A2
(en)
|
2010-03-17 |
2011-09-22 |
Axikin Pharmaceuticals Inc. |
Arylsulfonamide ccr3 antagonists
|
|
US11202853B2
(en)
*
|
2010-05-11 |
2021-12-21 |
Allergan, Inc. |
Porogen compositions, methods of making and uses
|
|
WO2011150201A2
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl amide compounds and methods of use thereof
|
|
WO2011150198A1
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
|
WO2011153197A1
(en)
|
2010-06-01 |
2011-12-08 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
|
|
CA2801003A1
(en)
|
2010-06-01 |
2011-12-08 |
Biotheryx, Inc. |
Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
|
|
NZ604018A
(en)
|
2010-06-07 |
2015-02-27 |
Novomedix Llc |
Furanyl compounds and the use thereof
|
|
MX347927B
(es)
|
2010-07-19 |
2017-05-19 |
Summa Health System |
Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
|
|
US20140200270A1
(en)
|
2013-01-11 |
2014-07-17 |
Summa Health System |
Vitamins c and k for treating polycystic diseases
|
|
EP2611502A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
|
WO2012030910A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
2-cycloquinazoline derivatives and methods of use thereof
|
|
US20130296363A1
(en)
|
2010-09-01 |
2013-11-07 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline derivatives for use as jak modulators
|
|
AU2011296024B2
(en)
|
2010-09-01 |
2015-05-28 |
Ambit Biosciences Corporation |
Quinazoline compounds and methods of use thereof
|
|
WO2012030912A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
|
EP2611792B1
(en)
|
2010-09-01 |
2017-02-01 |
Ambit Biosciences Corporation |
Hydrobromide salts of a pyrazolylaminoquinazoline
|
|
US20130303533A1
(en)
|
2010-09-01 |
2013-11-14 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
|
WO2012030914A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Boisciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
|
EP2611812A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Thienopyridine and thienopyrimidine compounds and methods of use thereof
|
|
US8912324B2
(en)
|
2010-09-01 |
2014-12-16 |
Ambit Biosciences Corporation |
Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
|
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
US20120088769A1
(en)
|
2010-10-11 |
2012-04-12 |
Axikin Pharmaceuticals, Inc. |
Salts of arylsulfonamide ccr3 antagonists
|
|
JP2013545749A
(ja)
|
2010-11-10 |
2013-12-26 |
インフィニティー ファーマシューティカルズ， インコーポレイテッド |
複素環化合物及びその使用
|
|
WO2012078649A1
(en)
|
2010-12-06 |
2012-06-14 |
Follica, Inc. |
Methods for treating baldness and promoting hair growth
|
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
|
AU2012205669B2
(en)
|
2011-01-10 |
2015-08-20 |
Infinity Pharmaceuticals Inc. |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
|
JP2014503597A
(ja)
|
2011-01-31 |
2014-02-13 |
セルジーン コーポレイション |
シチジンアナログの医薬組成物及びその使用方法
|
|
US9447187B2
(en)
|
2011-02-03 |
2016-09-20 |
Alexion Pharmaceuticals, Inc. |
Use of an anti-CD200 antibody for prolonging the survival of allografts
|
|
US9353100B2
(en)
|
2011-02-10 |
2016-05-31 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
|
|
EP2683383B1
(en)
|
2011-03-11 |
2017-11-29 |
Celgene Corporation |
Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2-6-dione in treatment of immune-related and inflammatory diseases
|
|
US20140088103A1
(en)
|
2011-03-28 |
2014-03-27 |
Mei Pharma, Inc. |
(fused ring arylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
EP2691384B1
(en)
|
2011-03-28 |
2016-10-26 |
MEI Pharma, Inc. |
(alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
|
|
AU2012236722A1
(en)
|
2011-03-28 |
2013-10-17 |
Mei Pharma, Inc. |
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
CN103842369A
(zh)
|
2011-03-31 |
2014-06-04 |
埃迪尼克斯医药公司 |
用于治疗病毒感染的化合物和药物组合物
|
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
|
EP2723735A4
(en)
|
2011-06-23 |
2015-02-18 |
Map Pharmaceuticals Inc |
NOVEL ANALOGUES OF FLUORO-ERGOLINE
|
|
WO2013003157A1
(en)
|
2011-06-28 |
2013-01-03 |
Yale University |
Cell-free tissued engineered vascular grafts
|
|
JP6027610B2
(ja)
|
2011-07-19 |
2016-11-16 |
インフィニティー ファーマシューティカルズ， インコーポレイテッド |
複素環式化合物及びその使用
|
|
US9056877B2
(en)
|
2011-07-19 |
2015-06-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
EP2751093A1
(en)
|
2011-08-29 |
2014-07-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2013039855A1
(en)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
AR088441A1
(es)
|
2011-09-12 |
2014-06-11 |
Idenix Pharmaceuticals Inc |
Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
|
|
WO2013049332A1
(en)
|
2011-09-29 |
2013-04-04 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
|
MY167575A
(en)
|
2011-10-14 |
2018-09-20 |
Ambit Biosciences Corp |
Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
|
|
TW201331221A
(zh)
|
2011-10-14 |
2013-08-01 |
Idenix Pharmaceuticals Inc |
嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物
|
|
US8586527B2
(en)
|
2011-10-20 |
2013-11-19 |
Jaipal Singh |
Cerivastatin to treat pulmonary disorders
|
|
CN104093399B
(zh)
|
2011-12-05 |
2018-03-13 |
卡穆鲁斯公司 |
鲁棒性控释肽制剂
|
|
AU2012355982A1
(en)
|
2011-12-19 |
2014-07-10 |
Map Pharmaceuticals, Inc. |
Novel iso-ergoline derivatives
|
|
US8946420B2
(en)
|
2011-12-21 |
2015-02-03 |
Map Pharmaceuticals, Inc. |
Neuromodulatory compounds
|
|
SMT202000008T1
(it)
|
2012-01-23 |
2020-03-13 |
Sage Therapeutics Inc |
Formulazione di steroide neuroattivo comprendente un complesso di allopregnanolone e solfobutil eter beta-ciclodestrina
|
|
WO2013130600A1
(en)
|
2012-02-29 |
2013-09-06 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
|
TW201341367A
(zh)
|
2012-03-16 |
2013-10-16 |
Axikin Pharmaceuticals Inc |
３，５－二胺基吡唑激酶抑制劑
|
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
AP3913A
(en)
|
2012-05-22 |
2016-11-26 |
Idenix Pharamaceuticals Inc |
D-amino acid compounds for liver disease
|
|
US9296778B2
(en)
|
2012-05-22 |
2016-03-29 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphate prodrugs for HCV infection
|
|
EP2852604B1
(en)
|
2012-05-22 |
2017-04-12 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
|
AU2013265210B2
(en)
|
2012-05-25 |
2016-09-15 |
Camurus Ab |
Somatostatin receptor agonist formulations
|
|
CA2875964C
(en)
|
2012-06-07 |
2018-01-02 |
Georgia State University Research Foundation, Inc. |
Seca inhibitors and methods of making and using thereof
|
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
|
AU2013294915C1
(en)
|
2012-07-26 |
2019-11-21 |
Camurus Ab |
Opioid formulations
|
|
PT2877155T
(pt)
|
2012-07-26 |
2020-12-18 |
Camurus Ab |
Formulações de opioides
|
|
TR201904785T4
(tr)
|
2012-08-09 |
2019-05-21 |
Celgene Corp |
(S)-3-(4-((4-MORFOLINOMETİL)BENZİL)OKSİ)-1-OKSOİZOİNDOLİN-2-il)PİPERİDİN-2,6-DİON HİDROKLORİDİN BİR KATI FORMU.
|
|
CN114939119A
(zh)
|
2012-08-09 |
2022-08-26 |
细胞基因公司 |
免疫相关和炎性疾病的治疗
|
|
PL2887944T3
(pl)
|
2012-08-21 |
2022-02-21 |
Sage Therapeutics, Inc. |
Allopregnanolon do leczenia lekoopornego stanu padaczkowego
|
|
CA2922849A1
(en)
|
2012-08-31 |
2014-03-06 |
Ixchel Pharma, Llc |
Agents useful for treating obesity, diabetes and related disorders
|
|
US9156799B2
(en)
|
2012-09-07 |
2015-10-13 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide CCR3 antagonists
|
|
US9968575B2
(en)
|
2012-09-27 |
2018-05-15 |
The Children's Medical Center Corporation |
Compounds for the treatment of obesity and methods of use thereof
|
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
|
SG11201502750UA
(en)
|
2012-10-08 |
2015-06-29 |
Idenix Pharmaceuticals Inc |
2'-chloro nucleoside analogs for hcv infection
|
|
US20140112886A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
|
EP2909222B1
(en)
|
2012-10-22 |
2021-05-26 |
Idenix Pharmaceuticals LLC |
2',4'-bridged nucleosides for hcv infection
|
|
KR102229478B1
(ko)
|
2012-11-01 |
2021-03-18 |
인피니티 파마슈티칼스, 인코포레이티드 |
Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
|
|
US20150272924A1
(en)
|
2012-11-08 |
2015-10-01 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
|
US20140140952A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Sp-Nucleoside Analog
|
|
EP2920195A1
(en)
|
2012-11-14 |
2015-09-23 |
IDENIX Pharmaceuticals, Inc. |
D-alanine ester of rp-nucleoside analog
|
|
AU2013352106B2
(en)
|
2012-11-30 |
2018-04-26 |
Novomedix, Llc |
Substituted biaryl sulfonamides and the use thereof
|
|
EP2935304A1
(en)
|
2012-12-19 |
2015-10-28 |
IDENIX Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
|
CA2895829A1
(en)
|
2012-12-21 |
2014-06-26 |
Map Pharmaceuticals, Inc. |
Novel methysergide derivatives
|
|
US9309275B2
(en)
|
2013-03-04 |
2016-04-12 |
Idenix Pharmaceuticals Llc |
3′-deoxy nucleosides for the treatment of HCV
|
|
WO2014137930A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
Thiophosphate nucleosides for the treatment of hcv
|
|
US20160024051A1
(en)
|
2013-03-15 |
2016-01-28 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
|
EP2981542B1
(en)
|
2013-04-01 |
2021-09-15 |
Idenix Pharmaceuticals LLC |
2',4'-fluoro nucleosides for the treatment of hcv
|
|
ES2834638T3
(es)
|
2013-05-30 |
2021-06-18 |
Infinity Pharmaceuticals Inc |
Tratamiento de cánceres usando moduladores de isoforma de PI3 cinasa
|
|
US10005779B2
(en)
|
2013-06-05 |
2018-06-26 |
Idenix Pharmaceuticals Llc |
1′,4′-thio nucleosides for the treatment of HCV
|
|
WO2015017713A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
|
CN105683182A
(zh)
|
2013-08-30 |
2016-06-15 |
埃姆比特生物科学公司 |
联芳基乙酰胺化合物及其使用方法
|
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
|
WO2015042375A1
(en)
|
2013-09-20 |
2015-03-26 |
Idenix Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
|
WO2015051336A1
(en)
|
2013-10-03 |
2015-04-09 |
David Wise |
Compositions and methods for treating pelvic pain and other conditions
|
|
PE20160685A1
(es)
|
2013-10-04 |
2016-07-23 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y usos de los mismos
|
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2015061204A1
(en)
|
2013-10-21 |
2015-04-30 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
|
WO2015066370A1
(en)
|
2013-11-01 |
2015-05-07 |
Idenix Pharmaceuticals, Inc. |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
|
HRP20190219T1
(hr)
|
2013-11-26 |
2019-03-22 |
The Children's Medical Center Corporation |
Spojevi za tretman pretilosti i postupci za njihovu uporabu
|
|
EP3074399A1
(en)
|
2013-11-27 |
2016-10-05 |
Idenix Pharmaceuticals LLC |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
|
BR112016011949A8
(pt)
|
2013-11-27 |
2020-04-28 |
Idenix Pharmaceuticals Llc |
composto, composição farmacêutica, e, uso dos mesmos
|
|
EP3083654A1
(en)
|
2013-12-18 |
2016-10-26 |
Idenix Pharmaceuticals LLC |
4'-or nucleosides for the treatment of hcv
|
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
|
SG10201808053XA
(en)
|
2014-03-19 |
2018-10-30 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
|
TWI705967B
(zh)
|
2014-03-20 |
2020-10-01 |
美商卡佩拉醫療公司 |
苯并咪唑衍生物及其醫藥組合物及使用方法
|
|
CA3175724C
(en)
|
2014-03-20 |
2024-01-09 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof
|
|
US20170209408A1
(en)
|
2014-04-03 |
2017-07-27 |
The Children's Medical Center Corporation |
Hsp90 inhibitors for the treatment of obesity and methods of use thereof
|
|
WO2015157559A2
(en)
|
2014-04-09 |
2015-10-15 |
Siteone Therapeutics, Inc. |
10',11'-modified saxitoxins for the treatment of pain
|
|
WO2015161137A1
(en)
|
2014-04-16 |
2015-10-22 |
Idenix Pharmaceuticals, Inc. |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
|
EP3142649B1
(en)
|
2014-05-12 |
2019-07-24 |
Conatus Pharmaceuticals, Inc. |
Treatment of the complications of chronic liver disease with caspase inhibitor emricasan
|
|
AU2015265607A1
(en)
|
2014-05-28 |
2016-11-17 |
Idenix Pharmaceuticals Llc |
Nucleoside derivatives for the treatment of cancer
|
|
US9527815B2
(en)
|
2014-06-18 |
2016-12-27 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
|
MY186839A
(en)
|
2014-06-19 |
2021-08-25 |
Takeda Pharmaceuticals Co |
Heteroaryl compounds for kinase inhibition
|
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
JP2017526713A
(ja)
|
2014-09-12 |
2017-09-14 |
トビラ セラピューティクス， インコーポレイテッド |
線維症を処置するためのセニクリビロック併用療法
|
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
|
KR102331856B1
(ko)
|
2014-10-21 |
2021-11-29 |
다케다 야쿠힌 고교 가부시키가이샤 |
결정 형태의 5-클로로-n4-[2-(디메틸포스포릴)페닐]-n2-｛2-메톡시-4-[4-(4-메틸피페라진-1-일)피페리딘-1-일]피리미딘-2,4-디아민
|
|
EP3209658A1
(en)
|
2014-10-24 |
2017-08-30 |
Biogen MA Inc. |
Diterpenoid derivatives and methods of use thereof
|
|
HUE049801T2
(hu)
|
2014-12-23 |
2020-10-28 |
Sma Therapeutics Inc |
3,5-diaminopirazol kináz inhibitorok
|
|
BR112017015510A2
(pt)
|
2015-01-20 |
2018-01-30 |
Xoc Pharmaceuticals Inc |
composto de fórmula estrutural (i), método de tratamento e/ou prevenção, método de agonização do receptor d2 em um indivíduo, método de antagonização do receptor d3 em um indivíduo, método de agonização do receptor 5-ht1d em um indivíduo, método de agonização do receptor 5-ht1a em um indivíduo, método de agonização seletiva do receptor 5-ht1d em vez do receptor 5-ht1b em um indivíduo, método de agonização seletiva do re-ceptor 5-ht2c em vez do receptor 5-ht2a ou 5-ht2b em um indivíduo, método de agonização do receptor 5-ht2c em um indivíduo, método de fornecimento de atividade antagonista funcional no receptor 5-ht2b ou receptor 5-ht7, e, método de fornecimento de atividade antagonista funcional nos receptores adrenérgicos em um indivíduo
|
|
CN113149982A
(zh)
|
2015-01-20 |
2021-07-23 |
Xoc制药股份有限公司 |
麦角灵化合物及其用途
|
|
HK1252245A1
(zh)
|
2015-05-27 |
2019-05-24 |
Idenix Pharmaceuticals Llc |
用於治疗癌症的核苷酸
|
|
WO2016210180A2
(en)
|
2015-06-23 |
2016-12-29 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors for treating neurological diseases or disorders
|
|
EA201890512A1
(ru)
|
2015-08-17 |
2018-09-28 |
Кура Онколоджи, Инк. |
Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы
|
|
US10160761B2
(en)
|
2015-09-14 |
2018-12-25 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
|
|
US10112953B2
(en)
|
2015-09-30 |
2018-10-30 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
|
IL284874B2
(en)
|
2015-10-30 |
2023-10-01 |
Neurocrine Biosciences Inc |
Valbenazine salts and polymorphs thereof
|
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
|
EP4455145A3
(en)
|
2015-12-02 |
2025-03-12 |
Astraea Therapeutics, LLC |
Piperidinyl nociceptin receptor compounds
|
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
|
LT3394057T
(lt)
|
2015-12-23 |
2022-06-27 |
Neurocrine Biosciences, Inc. |
Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
|
|
EP3397251A1
(en)
|
2015-12-31 |
2018-11-07 |
Conatus Pharmaceuticals, Inc. |
Methods of using caspase inhibitors in treatment of liver disease
|
|
MX385964B
(es)
|
2016-01-08 |
2025-03-18 |
Celgene Corp |
Formas sólidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il) metil)-2,2-difluoroacetamida y sus composiciones farmacéuticas y usos.
|
|
KR20180095094A
(ko)
|
2016-01-08 |
2018-08-24 |
셀진 코포레이션 |
암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도
|
|
EP3399978B1
(en)
|
2016-01-08 |
2020-09-09 |
Celgene Corporation |
Antiproliferative compounds, and their pharmaceutical compositions and uses
|
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
|
WO2017180589A1
(en)
|
2016-04-11 |
2017-10-19 |
Auspex Pharmaceuticals, Inc. |
Deuterated ketamine derivatives
|
|
US10047077B2
(en)
|
2016-04-13 |
2018-08-14 |
Skyline Antiinfectives, Inc. |
Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
|
|
WO2017184968A1
(en)
|
2016-04-22 |
2017-10-26 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
|
ES2912921T3
(es)
|
2016-04-29 |
2022-05-30 |
Fgh Biotech Inc |
Compuestos de pirazol disustituidos para el tratamiento de enfermedades
|
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US11339142B2
(en)
|
2016-09-07 |
2022-05-24 |
Fgh Biotech, Inc. |
Di-substituted pyrazole compounds for the treatment of diseases
|
|
MX390121B
(es)
|
2016-09-19 |
2025-03-20 |
Mei Pharma Inc |
Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas.
|
|
RS61745B1
(sr)
|
2016-11-03 |
2021-05-31 |
Kura Oncology Inc |
Inhibitori farneziltransferaze za upotrebu u tretiranju kancera
|
|
WO2018089692A1
(en)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
|
WO2018089427A1
(en)
|
2016-11-09 |
2018-05-17 |
Novomedix, Llc |
Nitrite salts of 1, 1-dimethylbiguanide, pharmaceutical compositions, and methods of use
|
|
JP7105774B2
(ja)
|
2016-12-01 |
2022-07-25 |
イグナイタ インコーポレイテッド |
がん治療のための方法
|
|
TW202345829A
(zh)
|
2016-12-02 |
2023-12-01 |
美商紐羅克里生物科學有限公司 |
戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
|
|
KR20230169457A
(ko)
|
2017-01-27 |
2023-12-15 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
US10137121B2
(en)
|
2017-02-21 |
2018-11-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
KR102003179B1
(ko)
|
2017-02-21 |
2019-07-23 |
쿠라 온콜로지, 인크. |
파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
EP3601326A4
(en)
|
2017-03-20 |
2020-12-16 |
The Broad Institute, Inc. |
COMPOUNDS AND METHODS OF REGULATING INSULIN SECRETION
|
|
CA3057978A1
(en)
|
2017-03-27 |
2018-10-04 |
The Regents Of The University Of California |
Compositions and method of treating cancer
|
|
CN110831945B
(zh)
|
2017-03-29 |
2023-08-08 |
赛特温治疗公司 |
用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
|
|
EP3601290B1
(en)
|
2017-03-29 |
2021-11-24 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
|
US20200179352A1
(en)
|
2017-04-26 |
2020-06-11 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
|
MA49141A
(fr)
|
2017-05-19 |
2020-03-25 |
Nflection Therapeutics Inc |
Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau
|
|
CA3063535A1
(en)
|
2017-05-19 |
2018-11-22 |
Nflection Therapeutics, Inc. |
Fused heteroaromatic-aniline compounds for treatment of dermal disorders
|
|
JP2020522504A
(ja)
|
2017-06-01 |
2020-07-30 |
エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ |
多環式化合物およびそれらの用途
|
|
WO2019023605A1
(en)
|
2017-07-27 |
2019-01-31 |
Allergan, Inc. |
PROSTACYCLINE RECEPTOR AGONISTS FOR BODY GREASE REDUCTION
|
|
MX2020001207A
(es)
|
2017-08-07 |
2020-03-20 |
Kura Oncology Inc |
Metodos de tratamiento del cancer con inhibidores de farnesiltransferasa.
|
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2019051477A1
(en)
|
2017-09-11 |
2019-03-14 |
Sage Therapeutics, Inc. |
METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION
|
|
RS66714B1
(sr)
|
2017-09-21 |
2025-05-30 |
Neurocrine Biosciences Inc |
Formulacija visoke doze valbenazina i sastavi, postupci i kompleti povezani sa njim
|
|
CA3076920A1
(en)
|
2017-10-04 |
2019-04-11 |
The Regents Of The University Of California |
Immunomodulatory oligosaccharides
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
MX2020003421A
(es)
|
2017-10-10 |
2020-07-20 |
Neurocrine Biosciences Inc |
Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
|
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
AU2019207491A1
(en)
|
2018-01-10 |
2020-07-30 |
Cura Therapeutics, Llc |
Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
|
|
WO2019139871A1
(en)
|
2018-01-10 |
2019-07-18 |
Cura Therapeutics Llc |
Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
|
|
EP3806856A1
(en)
|
2018-06-14 |
2021-04-21 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitor compounds, compositions, and methods relating thereto
|
|
EP3814327A1
(en)
|
2018-06-29 |
2021-05-05 |
Histogen, Inc. |
(s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
|
MA53239A
(fr)
|
2018-08-15 |
2022-05-04 |
Neurocrine Biosciences Inc |
Procédés d'administration de certains inhibiteurs de vmat2
|
|
WO2020072835A1
(en)
|
2018-10-03 |
2020-04-09 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
|
EP3873469A2
(en)
|
2018-11-01 |
2021-09-08 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
EP4233834A3
(en)
|
2018-11-20 |
2023-10-25 |
NFlection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks
|
|
MA55141A
(fr)
|
2018-11-20 |
2021-09-29 |
Nflection Therapeutics Inc |
Composés cyanoaryl-aniline pour le traitement d'affections de la peau
|
|
CA3120351A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
|
|
US12378240B2
(en)
|
2018-11-20 |
2025-08-05 |
Nflection Therapeutics, Inc. |
Naphthyridinone-aniline compounds for treatment of dermal disorders
|
|
EP3898609A1
(en)
|
2018-12-19 |
2021-10-27 |
Shy Therapeutics LLC |
Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
WO2020132700A1
(en)
|
2018-12-21 |
2020-06-25 |
Fgh Biotech Inc. |
Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
|
|
US20220071941A1
(en)
|
2018-12-21 |
2022-03-10 |
Kura Oncology, Inc. |
Therapies for squamous cell carcinomas
|
|
TWI839461B
(zh)
|
2019-02-06 |
2024-04-21 |
美商戴斯阿爾法股份有限公司 |
Il-17a調節物及其用途
|
|
WO2020180663A1
(en)
|
2019-03-01 |
2020-09-10 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2020181165A1
(en)
|
2019-03-07 |
2020-09-10 |
Conatus Pharmaceuticals Inc. |
Caspase inhibitors and methods of use thereof
|
|
US20220143006A1
(en)
|
2019-03-15 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
SG11202110472WA
(en)
|
2019-03-29 |
2021-10-28 |
Kura Oncology Inc |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
|
US20220168296A1
(en)
|
2019-04-01 |
2022-06-02 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
US20220305001A1
(en)
|
2019-05-02 |
2022-09-29 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
|
AU2020310190A1
(en)
|
2019-07-11 |
2022-02-24 |
Cura Therapeutics, Llc |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
|
AU2020311404A1
(en)
|
2019-07-11 |
2022-03-03 |
Cura Therapeutics, Llc |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
|
|
EP4003314B1
(en)
|
2019-07-26 |
2024-07-10 |
Espervita Therapeutics, Inc. |
Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
WO2021043771A1
(en)
|
2019-09-02 |
2021-03-11 |
Camurus Ab |
Formulations and treatment methods
|
|
JP7566889B2
(ja)
|
2019-09-16 |
2024-10-15 |
ダイス・アルファ・インコーポレイテッド |
Ｉｌ－１７ａモジュレーターおよびその使用
|
|
EP4034236A1
(en)
|
2019-09-26 |
2022-08-03 |
Abionyx Pharma SA |
Compounds useful for treating liver diseases
|
|
IL291398B2
(en)
|
2019-10-01 |
2025-05-01 |
Molecular Skin Therapeutics Inc |
Benzoxazinone compounds as dual inhibitors of KLK5/7
|
|
JP7600528B2
(ja)
*
|
2020-03-16 |
2024-12-17 |
株式会社リコー |
粒子の製造方法
|
|
EP4157271A1
(en)
|
2020-05-29 |
2023-04-05 |
Boulder Bioscience LLC |
Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
|
|
WO2021257828A1
(en)
|
2020-06-18 |
2021-12-23 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
EP4149471A4
(en)
|
2020-06-30 |
2024-07-10 |
Prosetta Biosciences, Inc. |
ISOQUINOLINE DERIVATIVES, PROCESSES FOR THE SYNTHESIS AND USES THEREOF
|
|
CN116368139A
(zh)
|
2020-08-14 |
2023-06-30 |
赛特温治疗公司 |
用于治疗疼痛的nav1.7的非水合酮类抑制剂
|
|
US20240124483A1
(en)
|
2021-01-27 |
2024-04-18 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
|
US20240309015A1
(en)
|
2021-01-27 |
2024-09-19 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
|
WO2022189856A1
(en)
|
2021-03-08 |
2022-09-15 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
|
IL305752A
(en)
|
2021-03-10 |
2023-11-01 |
Dice Molecules Sv Inc |
INTEGRIN INHIBITORS OF ALPHA V BETA 6 AND ALPHA V BETA 1 AND THEIR USES
|
|
WO2022226166A1
(en)
|
2021-04-22 |
2022-10-27 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
|
EP4347568A1
(en)
|
2021-05-27 |
2024-04-10 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
|
AU2022368836A1
(en)
|
2021-10-22 |
2024-05-02 |
Prosetta Biosciences, Inc. |
Novel host-targeted pan-respiratory antiviral small molecule therapeutics
|
|
MX2024005822A
(es)
|
2021-11-30 |
2024-05-28 |
Kura Oncology Inc |
Compuestos macrociclicos con actividad inhibidora de la farnesiltransferasa.
|
|
JP2025501308A
(ja)
|
2022-01-03 |
2025-01-17 |
ライラック セラピューティクス， インク． |
非環式チオールプロドラッグ
|
|
WO2023129577A1
(en)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
|
CN114404663A
(zh)
*
|
2022-01-07 |
2022-04-29 |
浙江瑞谷生物科技有限公司 |
一种具有炎症缓解特性的骨修复材料及其制备方法
|
|
CN114404664A
(zh)
*
|
2022-02-17 |
2022-04-29 |
浙江瑞谷生物科技有限公司 |
一种具备长效缓释的骨修复支架材料及其制备方法及应用
|
|
JP2025507621A
(ja)
|
2022-03-02 |
2025-03-21 |
ミトパワー， インク． |
ニコチン酸及びリボースから誘導体化した新規プロドラッグ
|
|
AU2023241822A1
(en)
|
2022-03-28 |
2024-09-26 |
Isosterix, Inc. |
Inhibitors of the myst family of lysine acetyl transferases
|
|
WO2023192904A1
(en)
|
2022-03-30 |
2023-10-05 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
|
AR129053A1
(es)
|
2022-04-14 |
2024-07-10 |
Bristol Myers Squibb Co |
Nuevos compuestos gspt1 y métodos de uso de los nuevos compuestos
|
|
KR20250006012A
(ko)
|
2022-04-15 |
2025-01-10 |
셀진 코포레이션 |
약물에 대한 림프종의 반응성을 예측하는 방법 및 림프종을 치료하는 방법
|
|
GEAP202516637A
(en)
|
2022-04-25 |
2025-03-25 |
Siteone Therapeutics Inc |
Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
|
|
AU2023265665A1
(en)
|
2022-05-05 |
2024-10-10 |
Biomarin Pharmaceutical Inc. |
Method of treating duchenne muscular dystrophy
|
|
JP2025531869A
(ja)
|
2022-09-09 |
2025-09-25 |
イノヴォ セラピューティクス、インコーポレイテッド |
ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物
|
|
EP4593826A1
(en)
|
2022-09-30 |
2025-08-06 |
Boulder Bioscience LLC |
Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
|
|
US20240139187A1
(en)
|
2022-10-12 |
2024-05-02 |
The Children's Medical Center Corporation |
Selective hypothalamus permeable hdac6 inhibitors for treatment of leptin-resistant obesity
|
|
EP4605084A2
(en)
|
2022-10-18 |
2025-08-27 |
Eluciderm Inc. |
2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- d]pyrimidin-4-ones for wound treatment
|
|
WO2024092040A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing bicyclic heteroaryl compounds
|
|
EP4608838A1
(en)
|
2022-10-26 |
2025-09-03 |
Protego Biopharma, Inc. |
Spirocycle containing pyridone compounds
|
|
US20240174673A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Pyridine Compounds
|
|
WO2024118810A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Cyclic pyrazole diamide ire1/xbp1s activators
|
|
EP4626864A1
(en)
|
2022-11-30 |
2025-10-08 |
Protego Biopharma, Inc. |
Linear heteroaryl diamide ire1/xbp1s activators
|
|
WO2024145662A1
(en)
|
2022-12-30 |
2024-07-04 |
Altay Therapeutics, Inc. |
2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors
|
|
WO2024226471A2
(en)
|
2023-04-24 |
2024-10-31 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for treating stxbp1 disorders
|
|
TW202448485A
(zh)
|
2023-05-05 |
2024-12-16 |
美商拜奧馬林製藥公司 |
肌萎縮蛋白外顯子跳躍寡核苷酸
|
|
AU2024344247A1
(en)
|
2023-09-19 |
2026-05-07 |
Kancure Pte. Ltd. |
Survivin-targeted compounds
|
|
WO2025072489A2
(en)
|
2023-09-27 |
2025-04-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use
|
|
IL327069A
(en)
|
2023-09-27 |
2026-05-01 |
Isosterix Inc |
Mist inhibitors
|
|
WO2025085416A1
(en)
|
2023-10-16 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1 compounds and methods of use of the compounds
|
|
WO2025085878A1
(en)
|
2023-10-20 |
2025-04-24 |
Altay Therapeutics, Inc. |
N-phenyl-3-(2,5-dioxopyrrolidin-1-yl)propanamide derivatives and similar compounds as dux4 inhibitors for the treatment of e.g. neuromuscular disorders
|
|
WO2025102082A1
(en)
|
2023-11-10 |
2025-05-15 |
Altay Therapeutics, Inc. |
Carbocyclic and heterocyclic stat3 inhibitor compositions and methods
|
|
GB2636969A
(en)
|
2023-11-24 |
2025-07-09 |
Ontrack Therapeutics Ltd |
Novel crystalline salt forms
|
|
WO2025147691A1
(en)
|
2024-01-04 |
2025-07-10 |
Innovo Therapeutics, Inc. |
Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
|
|
WO2025160286A1
(en)
|
2024-01-24 |
2025-07-31 |
Siteone Therapeutics, Inc. |
2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
|
|
WO2025179161A1
(en)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Protein degrading compounds
|
|
WO2025221809A1
(en)
|
2024-04-16 |
2025-10-23 |
Eluciderm Inc. |
2-aryl-quinazolin-4(3h)-one inhibitors for the treatment of diseases
|
|
TW202604501A
(zh)
|
2024-05-17 |
2026-02-01 |
美商賽特溫治療公司 |
用於治療疼痛之ＮＡｖ１．８之經取代之環烷基及雜環烷基抑制劑
|
|
WO2025255341A1
(en)
|
2024-06-05 |
2025-12-11 |
Protego Biopharma, Inc. |
Tetrahydrofuranyl ire1/xbp1s activators
|
|
WO2026013449A2
(en)
|
2024-07-11 |
2026-01-15 |
Sea4Us - Biotecnologia E Recursos Marinhos, Sa |
Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
|